{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hirsutism/management/management/","result":{"pageContext":{"chapter":{"id":"eb3e5264-aa93-5618-a326-1f9052e41577","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field 2d9c6e65-0b8e-42e5-aff2-f3b53b5cff98 --><h2>Scenario: Management of hirsutism</h2><!-- end field 2d9c6e65-0b8e-42e5-aff2-f3b53b5cff98 -->","summary":"Covers the management of women with hirsutism.","htmlStringContent":"<!-- begin item 5b685155-1b5d-4dd3-86c0-cb099c4312c3 --><!-- begin field efc3b3a8-7e10-4fdf-9485-acbc0159d93e --><p>From age 18 years onwards (Female).</p><!-- end field efc3b3a8-7e10-4fdf-9485-acbc0159d93e --><!-- end item 5b685155-1b5d-4dd3-86c0-cb099c4312c3 -->","topic":{"id":"f7bb546f-c63b-5f36-8592-742d53a300ba","topicId":"6cd0021b-eeb7-4f76-9627-4f095658d33a","topicName":"Hirsutism","slug":"hirsutism","lastRevised":"Last revised in July 2020","chapters":[{"id":"7f1b7b92-6387-5893-b9c1-1b0fe5e6921f","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ad41ddff-180c-5c56-9fa8-cfcaa4b301ac","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"4e6e27c3-ace8-5785-bc5d-74954333ce03","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"84d0d634-74f6-5808-8f94-da5030ec05c6","slug":"changes","fullItemName":"Changes"},{"id":"24cd5147-9eea-5049-abb9-bbff6b2e15e8","slug":"update","fullItemName":"Update"}]},{"id":"bccddc08-eaf5-58bc-b91c-222a0631380a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d59efd74-c7e8-5a58-88a9-274b74de9cc7","slug":"goals","fullItemName":"Goals"},{"id":"3e4b60ae-49dd-58fa-8977-9a8f93804089","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"fb5d6918-d9cd-57de-8ef8-09ac15afb519","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"fb74a918-ba53-56c2-b640-6a8b38dd4d52","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"0a97044d-161a-536d-99bd-e30a0b9553dd","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"ed166746-cb44-593f-aa91-2daa54e9df51","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"530429b5-0393-529c-874a-7270e7bccb64","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"2c5b6cec-8e35-5953-a425-773d40af6f62","slug":"definition","fullItemName":"Definition"},{"id":"7c04b952-69e3-54ba-abf5-964402df757c","slug":"causes","fullItemName":"Causes"},{"id":"1ab4046f-c4e7-520f-893f-e09d2db4390d","slug":"prevalence","fullItemName":"Prevalence"},{"id":"dce06012-6849-5ef4-ab2b-0c84dc64de89","slug":"complications","fullItemName":"Complications"}]},{"id":"0e4a9c3d-b4db-57a6-b036-9e01073ecafc","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"a58667b3-2a20-5be2-81aa-4b35ba1bc423","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"fc818766-2cdb-52a0-ad0e-7925d2deab29","slug":"assessment-for-an-underlying-cause","fullItemName":"Assessment for an underlying cause"},{"id":"3e40d667-a42d-56c7-a222-6eb858be7c6d","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"684a1492-2308-5cae-b75d-1460cf238959","fullItemName":"Management","slug":"management","subChapters":[{"id":"eb3e5264-aa93-5618-a326-1f9052e41577","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"61f39625-be0c-52a3-bdb4-7f1b9eaf0ffd","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"4573c138-4cd9-557f-9ff3-297c6187958a","slug":"topical-eflornithine","fullItemName":"Topical eflornithine"}]},{"id":"1d2fa7d5-926c-5ced-b5ff-0c103d1ddbbc","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"3154c9fd-0eb5-5ee3-8a69-a18ed1a66193","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"243b8cac-0f37-5266-bf46-8279e00461db","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"5fab04c2-7dc7-5ebd-89cd-f693a3cd663f","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b5b1cd8e-118a-5aab-bc89-4fa265c0b038","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d0d01f8a-60fc-5ef2-94a6-9d894ebe74d4","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"74f5177a-4053-5623-b286-63a07a583386","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"34dca8b6-44ff-5ef5-8816-48aa07f93aff","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"684a1492-2308-5cae-b75d-1460cf238959","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"46c35030-8b65-53ba-913f-837ad2097ed0","slug":"referral","fullItemName":"Referral","depth":3,"htmlHeader":"<!-- begin field b9a13153-c281-475d-b120-a995da0a6405 --><h3>When should I refer a woman with hirsutism?</h3><!-- end field b9a13153-c281-475d-b120-a995da0a6405 -->","summary":null,"htmlStringContent":"<!-- begin item 27c13341-6b86-46fd-85e7-6263a0de4338 --><!-- begin field 86c738ed-f99b-4c56-9276-6048cfb3c21e --><ul><li><strong>Refer urgently (within 2 weeks) to endocrinology if there is a possibility of an underlying adrenal or ovarian neoplasm. </strong><strong>Features of androgen-secreting tumours include:</strong><ul><li>Sudden onset or rapid progression of hair growth.</li><li>Signs of virilization (such as voice deepening, increased muscle bulk, and clitoromegaly).</li><li>A pelvic or abdominal mass.</li></ul></li><li><strong>Consider referral to endocrinology if another <a class=\"topic-reference internal-reference\" href=\"/topics/hirsutism/background-information/causes/\">underlying endocrine condition</a> is suspected that requires secondary care diagnosis and/or management</strong>. Use clinical judgement regarding urgency.</li><li><strong>For women in whom further <a class=\"topic-reference internal-reference\" href=\"/topics/hirsutism/diagnosis/assessment-for-an-underlying-cause/\">investigations</a> were performed, refer to endocrinology as appropriate. </strong>This includes women with:<ul><li>Raised testosterone level of > 4 nanomol/L (urgent referral is required if there is a possibility of an underlying adrenal or ovarian neoplasm or testosterone level is above 6–7 nanomol/L). </li><li>Elevated 17-hydroxyprogesterone levels.</li></ul></li></ul><!-- end field 86c738ed-f99b-4c56-9276-6048cfb3c21e --><!-- end item 27c13341-6b86-46fd-85e7-6263a0de4338 -->","subChapters":[{"id":"1ae86f6c-287c-59a2-911f-675830dcc614","slug":"basis-for-recommendation-1a8","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 933f220b-61dd-4fd4-80f7-bec06150e984 --><h4>Basis for recommendation</h4><!-- end field 933f220b-61dd-4fd4-80f7-bec06150e984 -->","summary":null,"htmlStringContent":"<!-- begin item 1a801865-327e-48e8-867a-f4519cfcd641 --><!-- begin field 4209c7ad-8aa7-4249-834c-e632b735a8c9 --><h5>Urgent referral if there are clinical features suggestive of an androgen-secreting tumour</h5><ul><li>This recommendation is extrapolated from clinical guidance on hyperandrogenism from the Primary Care Dermatology Society [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Primary Care Dermatology Society, 2017b</a>]. <ul><li>The clinical features of androgen secreting tumours are based on expert opinion in North American and Canadian guidance on hirsutism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Lui et al, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Martin et al, 2018</a>], Royal College of Obstetricians and Gynaecologists guidance on the long-term consequences of polycystic ovary syndrome [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">RCOG, 2014</a>], and expert opinion in a review article that notes virilisation is a red flag symptom which requires urgent referral to an endocrinologist [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Kini and Ramalingam, 2018</a>]. </li></ul></li></ul><h5>Referral if an underlying endocrine condition is suspected</h5><ul><li>This recommendation is pragmatic and is based on what CKS considers to be good clinical practice, reflecting expert opinion that in women with hirsutism not related to medication use, one focus of the evaluation is testing for endocrinopathies such as adrenal hyperplasia, Cushing syndrome, and androgen-secreting tumours [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Kini and Ramalingam, 2018</a>]. </li></ul><h5>Women with elevated serum total testosterone concentration</h5><ul><li>High testosterone levels warrant investigation to exclude conditions such as late-onset congenital adrenal hyperplasia or an androgen-secreting tumour [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">RCOG, 2014</a>]. However, the values and thresholds will depend upon the assay methodology and the normal range for that particular assay. <ul><li>Expert opinion in a guideline issued by the Royal College of Obstetricians and Gynaecologists on the long-term consequences of polycystic ovary syndrome suggests further investigation of high testosterone levels (greater than 5.0 nanomol/L or more than twice the upper limit of the normal reference range) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">RCOG, 2014</a>]. However, guidance on hyperandrogenism from the Primary Care Dermatology Society advises that women with a confirmed testosterone level above 4.0 nanomol/L should be referred to an endocrinologist, especially if they have recent onset relevant clinical signs [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Primary Care Dermatology Society, 2017b</a>]. This value was also supported by previous reviewers of this CKS topic. CKS recommends this lower value as a precautionary measure. </li><li>A previous expert reviewer of this CKS topic recommended urgent referral if testosterone level is above 6–7 nanomol/L, to exclude an androgen-secreting tumour.</li></ul></li></ul><h5>Women with elevated 17-hydroxyprogesterone levels</h5><ul><li>This recommendation is based on expert opinion in Canadian guidelines on <em>Hirsutism: Evaluation and treatment </em>which focuses on women in their reproductive years [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Lui et al, 2017</a>]. <ul><li>Levels of 17-hydroxyprogesterone of more than 6 nanomol/L are indicative of non-classical congenital adrenal hyperplasia (NCCAH) and require further investigation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">BMJ Best Practice, 2018</a>]. </li></ul></li></ul><!-- end field 4209c7ad-8aa7-4249-834c-e632b735a8c9 --><!-- end item 1a801865-327e-48e8-867a-f4519cfcd641 -->","subChapters":[]}]},{"id":"18b32679-8500-5de9-8fe7-e43148d56e9f","slug":"assessment-of-severity","fullItemName":"Assessment of severity","depth":3,"htmlHeader":"<!-- begin field 659d68ec-c530-4a9e-8c30-fa010d929c70 --><h3>How should I assess the severity of hirsutism?</h3><!-- end field 659d68ec-c530-4a9e-8c30-fa010d929c70 -->","summary":null,"htmlStringContent":"<!-- begin item 10f48332-1579-4baf-9415-1dbb3de989fa --><!-- begin field a1ee3d43-9cc0-4a4c-9c72-7805c22b489c --><ul><li><strong>Assess the severity of hair growth and the impact on the woman's quality of life, </strong>as this may guide treatment.</li><li><strong>A subjective approach is generally appropriate in primary care, </strong>using the woman's own perception of her condition and the extent it impacts on her quality of life.</li></ul><!-- end field a1ee3d43-9cc0-4a4c-9c72-7805c22b489c --><!-- end item 10f48332-1579-4baf-9415-1dbb3de989fa -->","subChapters":[{"id":"d1a7d08b-a4f4-58bc-8ffc-8c334c26e8a6","slug":"basis-for-recommendation-2ab","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 627377fd-6051-45a7-a0e1-eccd7a4db991 --><h4>Basis for recommendation</h4><!-- end field 627377fd-6051-45a7-a0e1-eccd7a4db991 -->","summary":null,"htmlStringContent":"<!-- begin item 2abe237c-0d74-4dd3-84ab-d95cad5b470d --><!-- begin field f98e933d-6a4d-447f-bdd4-7f734b1a06e0 --><h5>Assessment of severity of hair growth</h5><ul><li>The recommendation to assess severity is based on expert opinion in the Endocrine Society clinical practice guideline <em>Evaluation and Treatment of Hirsutism in Premenopausal Women </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Martin et al, 2018</a>]<strong> </strong>and Canadian guidelines on the evaluation and treatment of hirsutism in women of reproductive age [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Lui et al, 2017</a>].<strong> </strong></li><li>Using the modified Ferriman-Gallwey score, a cut off of 8 indicates excessive hair growth; mild hirsutism has been diagnosed in women with a score of less than 15, moderate hirsutism with a score of 16 to 25, and severe hirsutism with a score of more than 25 [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Lui et al, 2017</a>]. </li><li>However, the scoring system has a number of limitations as clinicians may not be familiar with its use, and the use of cosmetic measures make calculation of an accurate score difficult. It also has not been carefully validated in postmenopausal women. In addition, the effect of the excess hair on the woman in terms of distress caused needs to be taken into account when planning treatment as some women with low scores may have higher levels of distress than other women with higher scores [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Rothman and Wierman, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Martin et al, 2018</a>].  <ul><li>In a prospective observational study in 633 women, a Ferriman–Gallwey score of two or less was recorded in approximately 75% of women. Sixteen percent of these women considered themselves to be hirsute [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">DeUgarte et al, 2006</a>]. </li><li>Of the women with a Ferriman–Gallwey score of three or more, 69% considered themselves to be hirsute.<ul><li>Similarly, 70% of women with a Ferriman–Gallwey score of eight or more considered themselves to be hirsute.</li></ul></li></ul></li></ul><!-- end field f98e933d-6a4d-447f-bdd4-7f734b1a06e0 --><!-- end item 2abe237c-0d74-4dd3-84ab-d95cad5b470d -->","subChapters":[]}]},{"id":"9ea221e1-7ff1-508d-9765-58031ae40558","slug":"management-premenopausal-women","fullItemName":"Management (premenopausal women)","depth":3,"htmlHeader":"<!-- begin field 90f91da1-2103-46fc-827e-8db5d03340c9 --><h3>How should I manage hirsutism in premenopausal women?</h3><!-- end field 90f91da1-2103-46fc-827e-8db5d03340c9 -->","summary":null,"htmlStringContent":"<!-- begin item 0f7f32b1-7a2e-466e-9164-bcc0879341bd --><!-- begin field 4a3f7d0a-a69a-472e-b0d0-637531cb3422 --><p><strong>If <a class=\"topic-reference internal-reference\" href=\"/topics/hirsutism/management/management/#referral\">referral</a> is not indicated:</strong></p><ul><li><strong>Encourage weight loss </strong>in women who are overweight or obese. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/obesity/\">Obesity</a> for more information.</li><li><strong>Discuss <a class=\"topic-reference internal-reference\" href=\"/topics/hirsutism/management/management/#methods-of-hair-removal\">methods</a> of hair reduction and removal (such as shaving and waxing), </strong>as these will remain an important part of management.</li><li><strong>If hirsutism is mild and does not significantly impact on the woman's quality of life, </strong>reassure and advise that no additional treatment is required.</li><li><strong>If additional treatment is required:</strong><ul><li><strong>For women with facial hirsutism, </strong>offer topical eflornithine (depending on local prescribing policies).<ul><li>Advise that noticeable results take 6–8 weeks.</li><li>If no benefit is seen within 4 months of starting treatment, discontinue treatment and refer the woman to secondary care.</li><li>If improvement is seen, continued treatment is necessary to maintain the benefits. Once the cream is discontinued, hair growth returns to pretreatment levels within about 8 weeks.</li><li>Do not prescribe topical eflornithine to pregnant or breastfeeding women, or women younger than 19 years of age.</li><li>For information on advice to give, contraindications, cautions, adverse, effects, and drug interactions, see <a class=\"topic-reference internal-reference\" href=\"/topics/hirsutism/prescribing-information/\">Prescribing information</a>. </li></ul></li><li><strong>For all other women with hirsutism, offer a combined oral contraceptive (COC) containing ethinylestradiol as initial treatment, provided there are no contraindications.</strong> If the woman is at higher risk of venous thromboembolism<em> </em>(for example over the age of 39 years, or obese) consider a COC with the lowest effective dose of ethinylestradiol (usually 20 micrograms) and a low-risk progestogen.<em> </em>Discuss the risks associated with the use of the COC. <ul><li>See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> for detailed information on the contraindications and cautions of combined oral contraceptives (COCs) and the risks associated with their use.</li><li>The use of oral contraceptives for hirsutism is an off-label indication, except for Dianette<sup>® </sup>(cyproterone acetate and ethinylestradiol) which is licensed for the treatment of moderate to severe hirsutism in women of reproductive age.<ul><li>Any woman with a history meningioma should not take any cyproterone containing medications.</li></ul></li></ul></li></ul></li><li><strong>If COCs are contraindicated or have not worked (after treatment for 6 months or more), </strong>refer the woman to secondary care for consideration of a specialist treatment.</li><li><strong>Offer information on hirsutism,</strong> such as:<ul><li>NHS information on <a href=\"https://www.nhs.uk/conditions/hirsutism/\" data-hyperlink-id=\"14c1a058-318d-47f1-83b7-ab5f012c2311\">Excessive hair growth (hirsutism)</a>, available at <a href=\"https://www.nhs.uk/\" data-hyperlink-id=\"0fc4f31d-c2a5-4b12-8c07-ab5f012c2329\">www.nhs.uk</a>.</li><li>The British Association of Dermatologists leaflet: <a href=\"http://www.bad.org.uk/shared/get-file.ashx?id=89&itemtype=document\" data-hyperlink-id=\"34e3ee12-8f79-4c1d-b853-ab5f012c2337\">Hirsutism</a>, available at <a href=\"http://www.bad.org.uk/\" data-hyperlink-id=\"e649c626-c8b6-4caa-859e-ab5f012c2346\">www.bad.org.uk</a>.</li></ul></li></ul><!-- end field 4a3f7d0a-a69a-472e-b0d0-637531cb3422 --><!-- end item 0f7f32b1-7a2e-466e-9164-bcc0879341bd -->","subChapters":[{"id":"19a4ea7a-1344-5cf4-ac27-66fc14148ec9","slug":"methods-of-hair-removal","fullItemName":"Methods of hair removal","depth":4,"htmlHeader":"<!-- begin field d4d46b0d-d714-4193-b2dd-d3e6c323359a --><h4>Methods of hair removal</h4><!-- end field d4d46b0d-d714-4193-b2dd-d3e6c323359a -->","summary":null,"htmlStringContent":"<!-- begin item abcfeb6b-2505-499e-9ec6-e3ce5036f90a --><!-- begin field 6b80aacd-8a46-469e-876f-f284064280a9 --><ul><li><strong>Treatments that can be done in a domestic setting and offer temporary hair removal include:</strong><ul><li>Shaving — an easily available technique. However, it needs to be repeated frequently and leads to stubble; the blunt tip of shaved hair may give the illusion of thicker hair.</li><li>Waxing and plucking — these are effective techniques, but they can be painful and may cause scarring, folliculitis, and hyperpigmentation. </li><li>Chemical depilatory agents — dissolve hair, but may be associated with irritant dermatitis and hyperpigmentation.</li><li>Bleaching — this can mask the appearance of unwanted hair especially on the face, but it may also lead to skin irritation and skin discolouration.</li></ul></li><li><strong>Treatments carried out in specialist clinics may offer permanent hair reduction. They include:</strong><ul><li>Electrolysis — this uses a small current of electricity to destroy the hair follicle. It is effective, but is time-consuming, can be painful, and is impractical for hair removal over large areas. </li><li>Laser hair removal — can be used over larger areas. It can be painful and time-consuming. It is most effective in women with lighter skin and darker hair.</li></ul></li></ul><!-- end field 6b80aacd-8a46-469e-876f-f284064280a9 --><!-- end item abcfeb6b-2505-499e-9ec6-e3ce5036f90a -->","subChapters":[]},{"id":"81cc6e04-e3d1-57e3-8b6a-ae03a94716b2","slug":"basis-for-recommendation-d09","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field f3985645-9c7b-4325-9656-fcfe21a5cd69 --><h4>Basis for recommendation</h4><!-- end field f3985645-9c7b-4325-9656-fcfe21a5cd69 -->","summary":null,"htmlStringContent":"<!-- begin item d09add11-687a-4d80-9bb7-49493583c00e --><!-- begin field 7560b13c-dded-463d-9c7a-f497ca3fd31f --><h5>Weight loss</h5><ul><li>The recommendation to encourage lifestyle modifications including weight loss for women who are overweight or obese, especially those with polycystic ovary syndrome (PCOS), is supported by an Endocrine Society guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Martin et al, 2018</a>], and a number of experts [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Mihailidis et al, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Kini and Ramalingam, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Matheson and Bain, 2019</a>]. </li></ul><h5>Methods of hair removal</h5><ul><li>This recommendation reflects advice and information in North American and Canadian guidelines on the evaluation and management of hirsutism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Lui et al, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Martin et al, 2018</a>], and Primary Care Dermatology Society guidelines on hirsutism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Primary Care Dermatology Society, 2017a</a>].</li></ul><h5>Reassurance for mild hirsutism not significantly affecting quality of life</h5><ul><li>This recommendation is supported by a discussion in a systematic review stating that treatment may not be needed in women with mild hirsutism and no evidence of an endocrine disorder [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Barrionuevo et al, 2018</a>]. It is also extrapolated from North American guidelines on hirsutism. These acknowledge that treatment decisions should reflect the extent that excessive hair affects the woman and discuss the use of pharmacological treatments for women with 'patient-important' hirsutism (unwanted sexual hair growth of any degree causing sufficient distress for a woman to seek additional treatment) despite cosmetic measures [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Martin et al, 2018</a>].</li></ul><h5>Topical eflornithine for facial hirsutism</h5><ul><li>There is limited published evidence on the use of topical eflornithine for facial hirsutism.<ul><li>Evidence from open-label and randomized studies suggests that topical eflornithine may improve the appearance and growth of facial hair and reduce the 'overall bother' of facial hair [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">van Zuuren et al, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Martin et al, 2018</a>].</li></ul></li><li>Topical eflornithine is licensed for the treatment of facial hirsutism in women aged 19 years and older [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">ABPI, 2017</a>], and it is recommended in North American and Canadian guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Lui et al, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Martin et al, 2018</a>] and review articles on hirsutism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Mihailidis et al, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Kini and Ramalingam, 2018</a>]. </li><li>Information on advice to give women regarding eflornithine treatment is based on guidelines from the Endocrine Society [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Martin et al, 2018</a>], the British National Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Joint Formulary Committee, 2019</a>], and the manufacturer's Summary of Product Characteristics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">ABPI, 2017</a>]. </li></ul><h5>Combined oral contraceptives (COCs)</h5><ul><li>The recommendation to offer a COC first line for premenopausal women with hirsutism is largely based on expert opinion in the Endocrine Society clinical practice guideline <em>Evaluation and Treatment of Hirsutism in Premenopausal Women </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Martin et al, 2018</a>] and this recommendation is supported by Canadian guidelines on the evaluation and treatment of hirsutism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Lui et al, 2017</a>], clinical guidance from the Primary Care Dermatology Society [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Primary Care Dermatology Society, 2017a</a>], and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Kini and Ramalingam, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Matheson and Bain, 2019</a>]. <ul><li>Evidence in a systematic review and network meta-analysis has demonstrated efficacy of COCs compared with placebo for improving hirsutism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Barrionuevo et al, 2018</a>], although the effectiveness of a COC depends on the ethinylestradiol content and the progestogen it contains [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Primary Care Dermatology Society, 2017a</a>]. </li></ul></li><li>COCs reduce hyperandrogenism by suppression of luteinizing hormone secretion (thereby reducing ovarian androgen secretion) and by increasing the production of sex hormone-binding globulin (thereby increasing androgen binding and reducing free androgen levels) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Lui et al, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Martin et al, 2018</a>]. </li><li>Data from a French cohort study indicates that use of high dose cyproterone acetate containing 50–100 mg per tablet is associated with significantly increased risk of meningioma. Co-cyrindiol/Dianette®tablets containing cyproterone acetate with ethinylestradiol which are used for treatment of hirsutism in women of reproductive age contain only 2 mg of cyproterone acetate. The annual cumulative exposure to cyproterone acetate is therefore about 0.8 g. The MHRA advises that although exposure to this is low dose of cyproterone acetate has not been shown to increase risk of meningioma, an association is plausible and cannot be excluded [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">FSRH, 2020</a>].<ul><li>MHRA advice is therefore that women who have had a meningioma should not use any product containing cyproterone acetate. Women without a history of meningioma may use Co-cyprindiol/Dianette®for management of acne/hirsutism although they advise that clinicians should be vigilant for symptoms and signs of meningioma [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">FSRH, 2020</a>]. </li></ul></li></ul><h5>Choice of COC </h5><ul><li>Guidelines from the Primary Care Dermatology Society and Society of Obstetricians and Gynaecologists of Canada suggest that COCs containing non-androgenic progestogens (for example desogestrel or norgestimate) or antiandrogenic progestogens (for example cyproterone acetate, drospirenone) may be more effective [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Lui et al, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Primary Care Dermatology Society, 2017a</a>]. However, a particular oral contraceptive formulation is <em>not</em> recommended by a subsequent Endocrine Society guideline for treating hirsutism in most women [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Martin et al, 2018</a>].<ul><li>Although oral contraceptives containing cyproterone acetate or drospirenone were found to be associated with a slightly lower hirsutism severity score than other COCs, the Endocrine Society concluded that the differences were probably not clinically important [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Martin et al, 2018</a>]. A systematic review and network meta-analysis on treatment options for hirsutism also found similar effectiveness or trivial differences between COCs containing levonorgestrel, cyproterone acetate, or drospirenone and other COCs [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Barrionuevo et al, 2018</a>].</li></ul></li><li>Cyproterone acetate and drospirenone act as weak androgen receptor antagonists. Progestogens with low androgenicity include norgestimate, desogestrel, and gestodene [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Martin et al, 2018</a>]. COCs containing levonorgestrel or norithisterone are more androgenic [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Primary Care Dermatology Society, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Kini and Ramalingam, 2018</a>]. Levonorgestrel is the most androgenic progestogen but concerns on the effectiveness of COCs containing this for treating hirsuitism have not been supported by a meta-analysis. However, levonorgestrel is generally avoided in women with PCOS due to concerns about its adverse effects on metabolic biomarkers [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Martin et al, 2018</a>]. </li><li>The pragmatic recommendation to discuss the risks associated with COC use aims to ensure that the woman is fully informed. COCs are associated with a small increased risk of certain conditions, including venous thromboembolism (VTE) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">FSRH, 2019</a>]. Risk is further increased in women aged over 39 years and obese women taking the COC [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Martin et al, 2018</a>]. <ul><li>The incidence of VTE is 1.5–2 times higher in women using Dianette<sup>® </sup>(which contains cyproterone acetate) than in women using COCs containing levonorgestrel, and the VTE risk with Dianette<sup>® </sup>may be similar to that with COCs containing desogestrel, gestodene, or drospirenone [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Joint Formulary Committee, 2019</a>].</li></ul></li><li>Licensing information is based on the British National Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Joint Formulary Committee, 2019</a>] and the manufacturer's Summary of Product Characteristics for Dianette<sup>®</sup> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">ABPI, 2019</a>]. </li></ul><h5>Referral for specialist treatment</h5><ul><li>This recommendation is based on expert opinion in a review article stating that, for intractable cases, dermatology referral may be considered [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Matheson and Bain, 2019</a>]. The timescale is based on an Endocrine Society clinical practice guideline on <em>Evaluation and Treatment of Hirsutism in Premenopausal Women </em>which recommends a trial of 6 months of a pharmacological treatment before switching, changing the dose, or adding medication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Martin et al, 2018</a>]. </li><li>Other systemic treatments which have been suggested for the treatment of hirsutism include anti-androgens (for example cyproterone acetate, finasteride, flutamide, spironolactone), insulin-sensitizing drugs, and gonadotrophin-releasing hormone analogues [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Mihailidis et al, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Primary Care Dermatology Society, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Martin et al, 2018</a>]. CKS recommends referral to secondary care if COCs are contraindicated or have not worked because alternative treatments are not licensed for the treatment of hirsutism and some may have potentially serious adverse effects [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Lui et al, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Joint Formulary Committee, 2019</a>].  </li></ul><h5>Offering information on hirsutism</h5><ul><li>This recommendation reflects advice from the Primary Care Dermatology Society to provide a patient information leaflet to women with hirsutism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Primary Care Dermatology Society, 2017a</a>]. </li></ul><!-- end field 7560b13c-dded-463d-9c7a-f497ca3fd31f --><!-- end item d09add11-687a-4d80-9bb7-49493583c00e -->","subChapters":[]}]},{"id":"383da89e-4a44-56f7-baf0-0ec4eb212309","slug":"management-postmenopausal","fullItemName":"Management (postmenopausal)","depth":3,"htmlHeader":"<!-- begin field 89d1aa01-2919-47a9-9ea8-76df478ff29f --><h3>How should I manage hirsutism in postmenopausal women?</h3><!-- end field 89d1aa01-2919-47a9-9ea8-76df478ff29f -->","summary":null,"htmlStringContent":"<!-- begin item 150e6d6a-c8ec-4ee1-a3c4-6d7722dff100 --><!-- begin field 8eb619d1-ac4a-49c8-b622-96e233ba8249 --><p><strong>If <a class=\"topic-reference internal-reference\" href=\"/topics/hirsutism/diagnosis/assessment-for-an-underlying-cause/\">referral</a> is not indicated:</strong></p><ul><li><strong>Discuss <a class=\"topic-reference internal-reference\" href=\"/topics/hirsutism/management/management/#methods-of-hair-removal\">methods</a> of hair reduction and removal (such as shaving and waxing), </strong>as these will remain an important part of management.</li><li><strong>If hirsutism is mild and does not significantly impact on the woman's quality of life, </strong>reassure and advise that no additional treatment is required.</li><li><strong>Encourage weight loss </strong>in women who are overweight or obese. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/obesity/\">Obesity</a> for more information.</li><li><strong>If additional treatment is required:</strong><ul><li><strong>For women with facial hirsutism, </strong>offer topical eflornithine (depending on local prescribing policies).<ul><li>Advise that noticeable results take 6–8 weeks.</li><li>If no benefit is seen within 4 months of starting treatment, discontinue treatment and refer the woman to secondary care.</li><li>If improvement is seen, continued treatment is necessary to maintain the benefits. Once the cream is discontinued, hair growth returns to pretreatment levels within about 8 weeks.</li><li>For information on advice to give, contraindications, cautions, adverse, effects, and drug interactions, see <a class=\"topic-reference internal-reference\" href=\"/topics/hirsutism/prescribing-information/\">Prescribing information</a>. </li></ul></li><li><strong>For all other women with hirsutism, </strong>refer for initiation of specialist treatment.</li></ul></li></ul><!-- end field 8eb619d1-ac4a-49c8-b622-96e233ba8249 --><!-- end item 150e6d6a-c8ec-4ee1-a3c4-6d7722dff100 -->","subChapters":[{"id":"df0ea9c6-1882-5bf4-a237-0fc1a78eeda8","slug":"basis-for-recommendation-d31","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field b9efc149-5e54-46a2-8cd2-01c1544bf20d --><h4>Basis for recommendation</h4><!-- end field b9efc149-5e54-46a2-8cd2-01c1544bf20d -->","summary":null,"htmlStringContent":"<!-- begin item d31e8076-2d7b-4335-a54f-974b16dd1e99 --><!-- begin field 5dbce358-1f01-4020-a86f-5e698fa1204c --><p>There is very limited evidence for the specific treatment of hirsutism in post-menopausal women [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Blume-Peytavi et al, 2012</a>]. Recommendations are therefore largely based on the opinion of previous expert reviewers of this CKS topic and what is considered to be good clinical practice. In addition:</p><h5>Methods of hair removal</h5><ul><li>This recommendation is extrapolated from advice and information in North American and Canadian guidelines on the evaluation and management of hirsutism in premenopausal women [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Lui et al, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Martin et al, 2018</a>], and Primary Care Dermatology Society guidelines on hirsutism [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Primary Care Dermatology Society, 2017a</a>].</li></ul><h5>Reassurance for mild hirsutism not significantly affecting quality of life</h5><ul><li>This recommendation is supported by a discussion in a systematic review stating that treatment may not be needed in women with mild hirsutism and no evidence of an endocrine disorder [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Barrionuevo et al, 2018</a>]. It is also extrapolated from North American guidelines on hirsutism in premenopausal women. These acknowledge that treatment decisions should reflect the extent that excessive hair affects the woman and discuss the use of pharmacological treatments for women with 'patient-important' hirsutism (unwanted sexual hair growth of any degree causing sufficient distress for a woman to seek additional treatment) despite cosmetic measures [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Martin et al, 2018</a>]. </li></ul><h5>Weight loss</h5><ul><li>The recommendation to encourage lifestyle modifications including weight loss for women who are overweight or obese, especially those with polycystic ovary syndrome (PCOS), is supported by an Endocrine Society guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Martin et al, 2018</a>], and a number of experts [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Mihailidis et al, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Kini and Ramalingam, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Matheson and Bain, 2019</a>]. </li></ul><h5>Topical eflornithine for facial hirsutism</h5><ul><li>There is limited published evidence on the use of topical eflornithine for facial hirsutism.<ul><li>Evidence from open-label and randomized studies suggests that topical eflornithine may improve the appearance and growth of facial hair and reduce the 'overall bother' of facial hair [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">van Zuuren et al, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Martin et al, 2018</a>]. </li></ul></li><li>Topical eflornithine is licensed for the treatment of facial hirsutism in women aged 19 years and older [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">ABPI, 2017</a>], and it is recommended in North American and Canadian guidelines on hirsutism in premenopausal women [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Lui et al, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Martin et al, 2018</a>] and a review article on hair disorders in postmenopausal women [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Blume-Peytavi et al, 2012</a>]. </li><li>Information on advice to give women regarding eflornithine treatment is based on guidelines from the Endocrine Society [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Martin et al, 2018</a>], the British National Formulary [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Joint Formulary Committee, 2019</a>], and the manufacturer's Summary of Product Characteristics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">ABPI, 2017</a>].  </li></ul><h5>Referral for specialist treatment</h5><ul><li>This recommendation is based on expert opinion in a review article on hirsutism in women stating that, for intractable cases, dermatology referral may be considered​​​​​ [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Matheson and Bain, 2019</a>].</li><li>Other systemic treatments which have been suggested for the treatment of hirsutism include anti-androgens (for example cyproterone acetate, finasteride, flutamide, spironolactone), insulin-sensitizing drugs, and gonadotrophin-releasing hormone analogues [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Rothman and Wierman, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Blume-Peytavi et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Mihailidis et al, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Primary Care Dermatology Society, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Martin et al, 2018</a>]. CKS recommends referral to secondary care if hirsutism has failed to respond to treatment in primary care because these drugs are not licensed for the treatment of hirsutism and some may have potentially serious adverse effects [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Lui et al, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hirsutism/references/\">Joint Formulary Committee, 2019</a>].</li></ul><!-- end field 5dbce358-1f01-4020-a86f-5e698fa1204c --><!-- end item d31e8076-2d7b-4335-a54f-974b16dd1e99 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}